华为云智慧医疗专区开放公测，医疗创新ETF(516820)连续11天净流入

Group 1 - The core viewpoint of the news highlights the performance of the China Securities Pharmaceutical and Medical Device Innovation Index, which fell by 0.27% as of February 2, 2026, with mixed results among constituent stocks [1] - The top-performing stocks included Aimeike, which rose by 3.77%, and Dong'e Ejiao, which increased by 2.03%, while Xinhengcheng led the decline with a drop of 3.91% [1] - The Medical Innovation ETF experienced a decrease of 0.55%, with the latest price at 0.36 yuan, and has seen continuous net inflows over the past 11 days, totaling 198 million yuan [1] Group 2 - Everbright Securities emphasized that AI has become a core productivity driver in the medical new infrastructure, particularly in AI drug development and AI medical imaging, which are currently the most mature sectors [2] - The China Securities Pharmaceutical and Medical Device Innovation Index includes 30 listed companies with good profitability and growth potential, reflecting the overall performance of profitable and innovative pharmaceutical and medical device companies [2] - As of January 30, 2026, the top ten weighted stocks in the index accounted for 63.9% of the total, including WuXi AppTec and Mindray Medical [2]